167 related articles for article (PubMed ID: 24204567)
1. Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
Wang W; Zhang M; Sun W; Yang S; Su Y; Zhang H; Liu C; Li X; Lin L; Kim S; Okunieff P; Zhang Z; Zhang L
PLoS One; 2013; 8(10):e74272. PubMed ID: 24204567
[TBL] [Abstract][Full Text] [Related]
2. Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo.
Zhou J; Song S; He S; Wang Z; Zhang B; Li D; Zhu D
Int J Mol Med; 2013 Sep; 32(3):653-60. PubMed ID: 23846297
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
4. Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression.
Wang W; Li X; Sun W; Zhang L; Zhang M; Hong B; Lv G
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1597-605. PubMed ID: 22581262
[TBL] [Abstract][Full Text] [Related]
5. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
6. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
7. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells.
Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031
[TBL] [Abstract][Full Text] [Related]
8. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
9. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
10. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
11. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
Harashima N; Takenaga K; Akimoto M; Harada M
Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
[TBL] [Abstract][Full Text] [Related]
13. Decoy Receptor 3 Suppresses T-Cell Priming and Promotes Apoptosis of Effector T-Cells in Acute Cell-Mediated Rejection: The Role of Reverse Signaling.
Weng SC; Wen MC; Hsieh SL; Chen NJ; Tarng DC
Front Immunol; 2022; 13():879648. PubMed ID: 35720343
[TBL] [Abstract][Full Text] [Related]
14. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
15. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
16. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-κB dependent cFLIPL expression.
Liang DY; Huang W; Chang Q; Hou YQ
PLoS One; 2018; 13(2):e0191545. PubMed ID: 29444104
[TBL] [Abstract][Full Text] [Related]
17. Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis.
Seol JW; Chaudhari AA; Lee YJ; Kang HS; Kim IS; Kim NS; Park JH; Kim TH; Seol DW; Park SY
Oncol Rep; 2007 Sep; 18(3):523-9. PubMed ID: 17671697
[TBL] [Abstract][Full Text] [Related]
18. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).
You RI; Chang YC; Chen PM; Wang WS; Hsu TL; Yang CY; Lee CT; Hsieh SL
Blood; 2008 Feb; 111(3):1480-8. PubMed ID: 18006694
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
